Introduction
============

Autism spectrum disorder (ASD), a prevalent neurodevelopmental disorder characterized by impaired socio-communicational interactions and repetitive restricted behaviors, have polygenetic backgrounds ranging from heritable genetic variations to *de novo* mutations and copy number variants ([@nsw150-B10]; [@nsw150-B36]; [@nsw150-B27]). Variations in the oxytocin receptor gene (*OXTR*) are among such key genetic factors ([@nsw150-B36]; [@nsw150-B53]; [@nsw150-B32]), and previous researches reported associations between ASD and more than 20 single-nucleotide polymorphisms (SNPs) in *OXTR* ([@nsw150-B51]; [@nsw150-B56]; [@nsw150-B22]; [@nsw150-B28]; [@nsw150-B57]; [@nsw150-B30]; [@nsw150-B49]; [@nsw150-B53]; [@nsw150-B32]).

This ASD-*OXTR* relationship is supported by empirical evidence for seemingly beneficial effects of oxytocin on this developmental disorder. Although further confirmatory studies with a large-scale sample are necessary ([@nsw150-B40]), clinical trials reported that single-dose intranasal oxytocin administration mitigated autistic social behaviors and neural responses to socio-communicative information ([@nsw150-B20]; [@nsw150-B15]; [@nsw150-B4]; [@nsw150-B12]; [@nsw150-B44]; [@nsw150-B5]). Moreover, behavioral and neuroimaging studies employing neurotypical individuals added indirect evidence through identification of behavioral/neural links between several *OXTR* SNPs and ASD-associated social tendencies ([@nsw150-B39]; [@nsw150-B21]; [@nsw150-B41]; [@nsw150-B13]; [@nsw150-B54]; [@nsw150-B16]; [@nsw150-B26]). Collectively, these observations suggest that some *OXTR* variants in ASD individuals would alter their oxytocin-related neural circuits and partly induce their socio-communicational dysfunctions ([@nsw150-B36]; [@nsw150-B53]; [@nsw150-B32])

However, which *OXTR* SNPs crucially induce such biological effects on neural mechanisms underlying atypical social cognitions in ASD is still unclear ([@nsw150-B7]), and thus it remains unknown which *OXTR* SNPs significantly regulate oxytocin's effects on the social symptoms of the disorder. Although a recent study examined associations between three *OXTR* SNPs and oxytocin response in neurotypical adults ([@nsw150-B38]), no previous study employing ASD individuals has examined such relationships between oxytocin efficacy and genetic variability. In addition to such a biological significance, given a large variety of autistic responses to continual oxytocin administration ([@nsw150-B2]; [@nsw150-B9]; [@nsw150-B17]; [@nsw150-B46]; [@nsw150-B55]), it is also clinically essential to identify genetic variants of *OXTR* that enhance/deteriorate oxytocin's beneficial effects on ASD ([@nsw150-B26]; [@nsw150-B53]).

Here, we attempted to determine such biologically and clinically crucial *OXTR* SNPs that significantly affect oxytocin efficacy in ASD by applying a machine-learning algorithm to original datasets consisting of individual genetic information and behavioral/neural responses to the neuropeptide. The dataset about the oxytocin efficacy was extracted from our previous reports about a randomized, double-blind, placebo-controlled, cross-over within-participant trial ([@nsw150-B44]; [@nsw150-B3]). We employed not a univariate but multivariate analysis because it is crucial to evaluate collective effects of multiple SNPs in investigation of multigene disorders including ASD ([@nsw150-B29]; [@nsw150-B37]; [@nsw150-B50]). The machine-learning-based approach (here, support vector regression, SVR) was selected because, compared with a conventional general linear model, the technique can yield results that are more robust against noise and outliers, and have larger generalization capability ([@nsw150-B11]; [@nsw150-B43]). Moreover, like deep learning methods ([@nsw150-B19]), the current algorithm was designed to automatically select the most informative SNP sets without specific a priori assumptions.

Using these data and algorithm, we examined a hypothesis whether the behavioral and neural efficacy of oxytocin was predicted by patterns of specific *OXTR* SNP sets. Consequently, we identified the most informative combinations of *OXTR* SNPs for different types of oxytocin efficacy, and confirmed the different SNP sets could predict different oxytocin responses. The results implied distinct biological functions between several prominent *OXTR* SNPs.

Materials and methods
=====================

Overall analysis design
-----------------------

The current analysis procedure mainly consisted of the following six steps. (i) First, we excluded *OXTR* SNPs whose patterns were inappropriate for regression analysis ([Figure 1A](#nsw150-F1){ref-type="fig"}). (ii) Second, we prepared six indices of behavioral and neural oxytocin effects that had been already measured in our previous clinical trial ([@nsw150-B44]; [@nsw150-B3]). (iii) Third, using the machine-learning-based regression analysis (i.e., SVR), we calculated the associations between the oxytocin efficacy and all the possible sets of the *OXTR* SNPs, and searched for the most informative SNP sets ([Figure 1C](#nsw150-F1){ref-type="fig"}). (iv) Afterwards, we tested the robustness of the SNP selections by changing several analysis parameters. (v) Fifth, based on the selected informative SNP sets, we directly examined how accurately the SNP sets could predict the oxytocin efficacy. (vi) Finally, we evaluated the weight values assigned to the selected SNPs in the regression analysis, and examined whether the SNPs enhanced or deteriorated beneficial effects of oxytocin in high-functioning Japanese adult ASD males. Fig. 1.**(A)** Selection of SNPs of interest. Based on an established database (Affymetrix Genome-Wide Human SNP Array 6.0) and previous studies ([@nsw150-B53]; [@nsw150-B32]), 27 *OXTR* SNPs were identified for 38 participants with ASD ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). First, six SNPs were excluded because of their unbalanced ratios between their major and minor alleles across participants (more biased than 2:8), which could cause inaccurate machine-learning-based analysis. This 2:8 threshold is more conservative than that in previous literature ([@nsw150-B23]; [@nsw150-B45]). Second, we examined multicollinearity between the remaining 21 SNPs, and 11 SNPs were summarized to five patterns. The patterns of rs2268495 and rs4686302 were summarized to that of rs2268495 because the rs2268495 pattern was less biased than the rs4686302 pattern. Using this logic, the patterns of rs237877 and rs237878 were summarized to that of rs237878. Finally, 15 *OXTR* SNPs were selected ([Table 1](#nsw150-T1){ref-type="table"}). **(B)** Difference in across-participant SNP patterns. The remaining 15 *OXTR* SNPs showed ≥ 7 differences from each other, which is supposed to assure sufficient independency of these SNP patterns for the following regression analysis. **(C--E)** Analysis procedure. Using the 15 *OXTR* SNPs, we performed machine-learning-based regression analyses to determine specific SNP sets with sufficient information to predict behavioral and neural oxytocin efficacy, which had been measured in our previous trials ([@nsw150-B44]; [@nsw150-B3]). Six types of oxytocin efficacy was defined as (i) non-verbal communication score = increased number of NVJ (oxytocin--placebo); (ii) response smoothness = decreased reaction time for NVJ (placebo--oxytocin); (iii, iv) ACC/dmPFC activity = increased brain activity for NVJ in ACC/dmPFC (oxytocin--placebo; ACC, anterior cingulate cortex; dmPFC, dorsomedial prefrontal cortex); (v) dmPFC--ACC connectivity = increased NVJ-specific functional connectivity from dmPFC to ACC (oxytocin--placebo); (vi) NAA level in ACC = increased level of NAA in ACC (oxytocin--placebo).; NAA, N-acetylaspartate. For each of the six types of oxytocin response, we conducted machine-learning-based automatic selections of the most informative SNP sets, and examined its predictability using an independent test dataset. Briefly, we ranked SNPs based on MSEs of the regressions using them (panel D), and extracted the most informative SNPs based on the probability of each SNP appearing in top 10% least MSE SNP groups (panel E; see [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} for details).

Participants
------------

The current participants were the same as those in our previous clinical trials ([@nsw150-B44]) (i.e. ethnically homogeneous 38 high-functioning ASD males with age ≥ 20 and FIQ \> 80, 35 of which were non-medicated). The original ample size of the trial (*n* = 40) was determined by a power analysis based on our previous study about the relationship between an *OXTR* SNP (rs2254298) and the amygdalar volume in ethically the same cohort as the current study ([@nsw150-B21]; see [Supplementary Materials](#sup1){ref-type="supplementary-material"}). Two of the 40 original participants were excluded because their behavioral responses were not recorded due to technical problems in the trial.

Their ASD diagnoses were made by experienced psychiatrists (HY/HK) with the strict criteria of DSM-R IV after more than 2 months of follow-up examinations, and were validated by certified psychiatric psychologists with Japanese version of ADI-R (HK) ([@nsw150-B34]) and/or ADOS (Dr Miho Kuroda) ([@nsw150-B33]). All the participants had sufficiently high IQs ranging from average to above average in the full scale of WAIS-R, Japanese version. The study protocol was registered in University Hospital Medical Information Network clinical trial registry (UMIN000002241/000004393). Written informed consent was obtained from all the participants.

*OXTR* genotyping
-----------------

Among 27 *OXTR* SNPs of interest, 21 SNPs were selected based on Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA; non-\* SNPs in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}), whereas the other six SNPs were included according to previous reports ([@nsw150-B53]; [@nsw150-B32]; \* SNPs in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). TaqMan genotyping platform was used to genotype these SNPs (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA; see [Supplementary Materials](#sup1){ref-type="supplementary-material"}).

Step 1: exclusion of SNPs inappropriate for regression analysis
---------------------------------------------------------------

First, we excluded *OXTR* SNPs whose distribution patterns across participants could induce inaccurate calculations in the following analyses ([Figure 1A](#nsw150-F1){ref-type="fig"}). Technically, SNPs whose across-participant distributions were too biased (here, a major allele is seen in \>80% of the sample) were removed because they could cause overfitting in machine-learning procedures ([@nsw150-B6]). This threshold is more conservative than those adopted in previous machine-learning-based studies ([@nsw150-B23]; [@nsw150-B45]).

Second, we examined multicollinearity ([@nsw150-B25]) between the remaining SNPs by calculating the difference in the across-participants SNP patterns, which was defined as min(\|SNP~*i*~ -- SNP~*j*~\|, *N*~participant~ -- \|SNP~*i*~ -- SNP~*j*~\|), where *N*~participant~ denotes the number of participants. SNPs whose differences were ≤ 2 were summarized into one of them ([Figure 1B](#nsw150-F1){ref-type="fig"}). Consequently, allelic information of 15 *OXTR* SNPs was used in the following analysis ([Table 1](#nsw150-T1){ref-type="table"}). Table 1.SNPs of interestSNPAllele assigned to 2Allele assigned to 1rs11914920/rs10490801AA/TTG carrier/C carrierrs2270463GGA carrierrs2072582GGA carrierrs4686302CCT carrierrs237877/rs237878CC/TTT carrier/C carrierrs2139184CCT carrierrs11706648AAG carrierrs237887GGA carrierrs2254295/rs2254298/rs2268491TT/GG/CCC carrier/A carrier/T carrierrs11131149GGA carrierrs53576GGA carrierrs237895TTC carrierrs2268495/rs4686302GG/CCA carrier/T carrierrs237900GGA carrierrs17049528/rs6777726GG/GGA carrier/A carrier

Step 2: identification of six oxytocin efficacy
-----------------------------------------------

The data for the six types of oxytocin efficacy ([Figure 1C](#nsw150-F1){ref-type="fig"}) were extracted from our previous studies ([@nsw150-B44]; [@nsw150-B3]).

Five of the six responses were measured using a social cognition task that was designed to recruit cognitive ability to smoothly resolve conflicts between verbal and non-verbal social information ([@nsw150-B47]; [@nsw150-B48]). This ability is implicitly used to understand jokes and satires in typically developing (TD) individuals.

In this task, participants were presented with a series of short videos. In each video, a professional actor spoke an emotional phrase (positive/negative verbal information) with emotional facial and vocal expression (positive/negative non-verbal information), and the participants were asked to judge whether the actor in the video felt like a friend or foe.

By focusing on responses to movie stimuli whose verbal information was incongruent with non-verbal information (e.g. a positive phrase was spoken with negative facial and voice expression), we first characterized individual social behaviors. For example, a 'friend' judgment for an actor speaking a negative phrase with positive facial and vocal expressions was regarded to be a decision mainly based on non-verbal information, whereas a 'foe' judgment for the same actor was regarded as verbal-information-based judgments. Afterwards, we estimated brain activity specific to such non-verbal-information-based judgments (NVJs), and identified brain mechanisms underlying atypical social behaviors in ASD individuals.

In fact, this social cognitive task enabled us to detect ASD-specific behavioral and neural responses that were linked with the severity of the social symptoms of autism ([@nsw150-B47]). When compared with TD individuals, ASD individuals were more likely to emphasize verbal information during such friend/foe judgments. The number of NVJs was significantly less in ASD group than in TD group, and the reaction time for NVJs was also longer in ASD individuals. In addition, during this NVJ behavior, ASD individuals showed significantly less brain activity in two medial prefrontal regions than TD individuals (anterior cingulate cortex, ACC; dorsomedial prefrontal cortex, dmPFC). Notably, these behavioral and neural responses were correlated with the severity of the socio-communicational symptoms of ASD.

Moreover, this task allowed us to detect five behavioral and neural effects of single-dose intranasal oxytocin (24IU) on social symptoms of autism ([@nsw150-B48]). When compared with placebo, single-dose oxytocin significantly increased the number of NVJs and reduced the reaction time for NVJs with recovering brain activity of the two brain regions (ACC and dmPFC) and bidirectional functional connectivity between the two regions. Furthermore, using this task, we have recently reported significant behavioral and neural effects of oxytocin even in a long-term continual administration ([@nsw150-B46]).

Note that in our previous clinical trial ([@nsw150-B48]), we had attempted to reduce behavioral and neural effects of practice in this type of stroop task by (i) introducing sufficient training sessions before the MRI scanning and (ii) randomizing the order of drug administration. Regarding (i), the participants were asked to undergo more than 20 'friend or foe' judgment trials with movie stimuli that were not included in the following MRI experiments. This training session were expected to saturate behavioral/neural responses to the tasks in each participant, and hence reduce the practice effects within day and within participant. Regarding (ii), practice effects over the different experiment days were supposed to be controlled by randomizing drug administration days across participants (i.e. randomization of oxytocin and placebo days in a crossover design).

Given these previous observations, it is reasonable to assume that these five types of behavioral and neural response are sensitive and specific enough to represent oxytocin's efficacy on autistic social symptoms. To reduce confounding effects of selection bias, we used all of them as outcome measures to investigate relationships between types of *OXTR* SNP and oxytocin efficacy as follows ([Figure 1C](#nsw150-F1){ref-type="fig"}): (i) non-verbal communication score = increased number of NVJs (oxytocin--placebo); (ii) response smoothness = decreased reaction time for NVJ (placebo--oxytocin); (iii, iv) ACC/dmPFC activity = increased brain activity for NVJs in ACC/dmPFC (oxytocin--placebo); (v) dmPFC--ACC connectivity = increased NVJ-specific functional connectivity from dmPFC to ACC (oxytocin--placebo).

In addition, because oxytocin affected the neurochemical substance level ([@nsw150-B3]), (vi) increased level of N-acetylaspartate (NAA) in ACC (oxytocin--placebo) was adopted as the sixth oxytocin efficacy. To reduce effects of outliers on the following regressions, these oxytocin efficacy values were normalized.

Step 3: search for informative SNP sets with SVR
------------------------------------------------

We then searched for the informative SNP sets that accurately predicted each oxytocin efficacy by implementing a SNP ranking algorithm based on a *ν*-linear SVR ([@nsw150-B6]; [@nsw150-B31]) ([Figure 1C](#nsw150-F1){ref-type="fig"}, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) in MATLAB R2014b (MathWorks) with LIBSVM package ([www.csie.ntu.edu.tw/∼cjlin/libsvm/](http://www.csie.ntu.edu.tw/~cjlin/libsvm/)). We used a linear SVR rather than non-linear one to avoid overfitting and enable straight-forward interpretation of weight values later ([@nsw150-B6]).

First, the SNP information was binarized (major/minor allele as 2/1; [Table 1](#nsw150-T1){ref-type="table"}). After choosing one of the six oxytocin efficacy indices, we divided the SNP and response data to test data (consisting of one participant data) and training data (consisting of the others' data) in a leave-one-out-cross-validation (LOOCV) manner ([@nsw150-B6]).

Second, using the training data, we fitted the binary information of certain *n* SNPs (1 ≤ *n* ≤ 15) to the oxytocin efficacy using a SVR, and calculated the mean square error (MSE) of the regression ([@nsw150-B31]). In each SNP number (*n*), we repeated this fitting and MSE calculation for all the possible 15!/*n*!(15--*n*)! SNP sets, and ranked the SNP sets according to the MSE ascending order ('SNP Ranking' in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

We did not directly adopt the SNP set with the smallest MSE as the most informative SNP combination, because the MSE calculations can be noisy owing to the current limited dataset size and may be simply a result of overfitting ([@nsw150-B6]). Instead, we first calculated the probability of how often each SNP appeared in the Top10% most informative SNP sets (i.e. Top10% of rankings; [Figure 1E](#nsw150-F1){ref-type="fig"}). Moreover, to reduce effects of inaccurate calculations due to so-called 'curse of dimension' (i.e. here, imprecise estimations at a large *n*; [@nsw150-B6]), we focused on a range whose MSE calculations were relatively stable (i.e. 1 ≤ *n* ≤ 10; [Figures 1E](#nsw150-F1){ref-type="fig"} and [2A](#nsw150-F2){ref-type="fig"}), and averaged the appearance probability within the range. We finally selected sets of the most informative SNPs based on this average appearance probability ('SNP Selection' in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). These selection procedures were anticipated to improve the robustness of the SNP selection. Fig. 2.Informative SNPs. **(A, B)** Minimum error and size of SNP sets. Panel A shows representative relationships between the number of SNPs used for the SVR (*n*) and the minimum (min) MSE, which were estimated using data excluding those obtained from Participant no. 1 (Pt1). Panel B shows associations between the SNP number and min MSE in all patterns of training data sets. The vertical axes show ID of the participants whose data were excluded from the training data. For all the six types of oxytocin efficacy, the min MSE was relatively stable between *n* = 1 and 10, whereas in *n* \> 10, the min MSE gradually increased. MSE, mean square error. **(C)** Probability of SNP appearance in the Top10% informative SNP sets. The bar graphs show how often each SNP was included in the Top10% informative SNP groups when the analysis used data excluding those of Pt1. The neighboring color boxes show the appearance probability patterns in all the training data sets. The appearance probabilities were calculated as an average across 1 ≤ *n* ≤ 10. \* and \*\* represent Bonferroni-corrected *P* values (\* \<0.05; \*\*\< 0.01) in residual tests following chi-squared tests. †shows that the distribution of the appearance probability is significantly rare in post-hoc permutation tests (*P*~Bonferroni-corrected~ \< 0.05). The dash lines represent the value of by-chance appearance probability (i.e. 1/15 = 0.067). Colored bars indicate the significantly informative SNPs. For every type of the oxytocin efficacy, the informative SNP sets with significantly high appearance probability were the same across all the 38 different training datasets

Distributions of the appearance probability were evaluated by chi-squared tests and post-hoc residual tests, which was further validated by permutation tests with 10 000 random permutations.

Statistical evaluations were corrected in Bonferroni manner (for the chi-squared tests across six oxytocin effects, *α=* 0.05/6; for the post-hoc residual test across 15 SNPs, *α=* 0.05/15; for the permutation tests across six oxytocin effects, *α=* 0.05/6). This Bonferroni correction may be too conservative because the five oxytocin efficacy indices were likely to be correlated with each other (absolute value of Fisher-transformed correlation coefficients: ∣Z∣ = 0.47 ± 0.22, mean ± SD). However, given the current relatively limited sample size, we attempted to reduce the risk of overestimation by adopting this conservative correction method.

Step 4: tests of the robustness of the informative SNPs selections
------------------------------------------------------------------

We then examined the robustness of the SNP selections by changing (i) the definition of the top informative SNP sets and (i) the SNP number (*n*) used to calculate the average appearance probability. To test (i), we repeated the SNP selection procedure by changing the definition of the top informative SNP groups from Top5% to Top20% by one point ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}A). To test (ii), we repeated the same analysis by changing the range of *n* from 1 ≤ *n* ≤ 10 to 5 ≤ *n * ≤ 10 ([Supplementary Figure 4A](#sup1){ref-type="supplementary-material"}) and moving the range from 1 ≤ * n* ≤ 5 to 6 ≤ *n * ≤ 10 ([Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}).

Step 5: direct evaluation of predictability of the selected SNPs
----------------------------------------------------------------

We then directly evaluated how accurately the selected SNP sets predicted the oxytocin efficacy. The predictability was estimated in a LOOCV manner. For each oxytocin efficacy, we determined regression weights of the informative SNPs using training data (datasets recorded from 37 individuals), applied the weights to the test SNP data (a dataset derived from the remaining one individual), and calculated the predicted value of the oxytocin efficacy. We repeated these procedures for every training dataset (i.e. 38 different datasets), and obtained efficacy prediction for all the 38 individuals. We then evaluated the similarity between these predicted and real responses by performing *F* tests on the fitness of the regressions and by calculating Pearson correlation coefficients between them.

We also examined the accuracy in distinguishing individuals with high oxytocin sensitivity from those with relatively less sensitivity by counting the number of the participants for whom predicted responses had the same directions as empirically observed responses (i.e. both \> 0 or both \< 0; participants in the light gray areas in [Figure 3B](#nsw150-F3){ref-type="fig"}). Such classification using 'zero' as a threshold was justified because the data were normalized prior to the SVR calculations. Fig. 3.Prediction of oxytocin efficacy based on *OXTR* SNPs. **(A)** Regression accuracy. The X axes show predicted oxytocin efficacy calculated by SVR using the most informative SNP sets (colored SNPs in [Figure 2C](#nsw150-F2){ref-type="fig"}), whereas the Y axes show normalized values of the empirically observed effects. Each circle represents a participant. For all the oxytocin effects, we observed significantly high correlations between the predicted and empirical values (*P*~Bonferroni-corrected~ \< 0.05; [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). To reduce the effect of outliers, all the indices of oxytocin efficacy were normalized prior to the regression analysis. **(B, C)** Based on these regression analyses, we calculated accuracy of this machine-learning technique for classifying participants into an oxytocin-responsive group and a relatively irresponsive group. As schematically shown in panel B, participants plotted in the light gray areas are regarded as correctly classified ones, whereas those in the dark gray areas are not. For all six types of oxytocin efficacy, the classification accuracy was significantly higher (\**P*~Bonferroni-corrected~ \< 0.05; \*\**P*~Bonferroni-corrected~ \< 0.01 in binominal tests; panel C). **(D)** Weight values assigned to the informative SNPs. We examined the weight values assigned to the informative SNPs by the SVR analyses. The Y axes represent weight values averaged across four independent SVR calculations using four independent datasets. Notably, all the informative SNPs show consistent directions across different types of oxytocin efficacy (e.g. weights assigned to rs53576 are significantly positive in all the responses). \**P*~Bonferroni-corrected~ \< 0.05; \*\**P*~Bonferroni-corrected~ \< 0.01, in one-sample *t*-tests. Error bars, SEM. See also [Table 2](#nsw150-T2){ref-type="table"}.

These statistical evaluations were corrected in Bonferroni method (*α=* 0.05/6).

Step 6: examination of functionality of the selected SNPs
---------------------------------------------------------

Finally, we examined weights assigned in the linear SVR. To ensure the independence between the estimated weights, we first randomly divided the 38 participants into four groups (*n* = 9, 9, 10 and 10). Within each group, we performed the same SNP selections for the six oxytocin efficacy. After confirming that the appearance probability of the originally selected informative SNPs was above a chance level in every group, we estimated regression weights for the selected SNPs. Using these independently calculated four weights for each informative SNP, we conducted one-sample *t*-tests and examined whether each weight was significantly different from zero.

Multiple comparisons in these tests were corrected in Bonferroni method (*α=* 0.05/\[number of the informative SNPs for each type of oxytocin efficacy\]).

Results
=======

Exclusion of SNPs inappropriate for regression analysis
-------------------------------------------------------

We first excluded six of the 27 *OXTR* SNPs whose major allele types were too dominant across participants (\>80% of the sample) and could cause inaccurate regression analysis ([Figure 1A](#nsw150-F1){ref-type="fig"}, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Then, we summarized 11 of the remaining 21 SNPs into five patterns because of their high multicollinearity, and obtained 15 SNPs ([Table 1](#nsw150-T1){ref-type="table"}; see also legends for [Figure 1A](#nsw150-F1){ref-type="fig"}), whose distributions were relatively unbiased and sufficiently different from each other (difference ≥ 7, variance inflation factor \< 1.9; [Figure 1B](#nsw150-F1){ref-type="fig"}). This procedure to avoid high multicolinearity is qualitatively equivalent to a protocol to assure linkage disequilibrium between the SNPs ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In the following analysis, we investigated associations between the oxytocin efficacy and patterns of these 15 *OXTR* SNPs.

Selection of the most informative SNP sets
------------------------------------------

Next, using the 15 SNPs, we searched for the most informative SNP combinations that could robustly and accurately predict individual oxytocin efficacies. For this purpose, we evaluated the probability of each SNP appearing in Top10% informative SNP sets ([Figure 1C](#nsw150-F1){ref-type="fig"}, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Because the regression errors (i.e. minimum MSEs) were relatively stable when using 1--10 SNPs for all the oxytocin effects in all the patterns of the training datasets ([Figure 2A and B](#nsw150-F2){ref-type="fig"}), we calculated the appearance probability based on these stable results of the regressions analysis.

As a result, we first confirmed that the distributions of the appearance probability across 15 SNPs were significantly skewed compared with a uniform distribution for every oxytocin efficacy (***x***^2^~(14)~ \> 118, *P*~Bonferroni-corrected~ \< 0.001 in chi-squared tests; [Figure 2C](#nsw150-F2){ref-type="fig"}). Then, we found that the appearance probabilities of several specific SNPs were significantly higher than the chance level (SNPs indicated with colored bars in [Figure 2C;](#nsw150-F2){ref-type="fig"}*Z* \> 4.1, *P*~Bonferroni-corrected~ \< 0.05 in *posthoc* residual tests; *P* \< 0.0075, *P*~Bonferroni-corrected~ \< 0.05 in *posthoc* permutation tests). These results suggest that such SNPs with significant high appearance probability can be regarded as the most informative SNP sets.

To avoid circular analysis, these entire SNP selection procedures were conducted after dividing the dataset to training and test datasets according to a LOOCV manner ([Figure 1C](#nsw150-F1){ref-type="fig"}, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Notably and coincidently, the informative SNP sets showing significantly high appearance probability were the same across all the 38 different training datasets for every oxytocin response (color boxes in [Figure 2C](#nsw150-F2){ref-type="fig"}).

Examination of robustness of SNP selections
-------------------------------------------

We then examined the robustness of these SNP selections by changing several analysis parameters. First, we repeated the SNP selection procedure with changing the definition of 'top informative groups' from Top5% to Top20% lowest MSE groups by one point ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). Consequently, for every oxytocin efficacy, all of the most informative SNPs originally selected in [Figure 2C](#nsw150-F2){ref-type="fig"} were consistently identified as being significantly informative (*P*~Bonferroni-corrected~ \< 0.05 in residual tests) in \>85% of the parameter changes, whereas the other SNPs were not selected so often (≤ 50% of the changes; [Supplementary Figure S3B and C](#sup1){ref-type="supplementary-material"}). These results show the robustness of the original SNP selections against changes of the definition of 'top informative groups'.

Second, we also confirmed the robustness of the SNP selections by changing the SNP number range (*n*) used for calculations of the appearance probability ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). Even after the range width was changed from 10 to five, all the original informative SNPs shown in [Figure 2C](#nsw150-F2){ref-type="fig"} were always selected as informative ones, whereas the other SNPs were not so consistently chosen (≤40% of the changes; [Supplementary Figure S4B and C](#sup1){ref-type="supplementary-material"}). Moreover, this robustness was still observed when we moved the window for the target SNP number form 1 ≤  *n* ≤ 5 to 6 \< *n* ≤ 10 ([Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}): for every oxytocin efficacy, the originally-selected SNPs were almost always significantly informative (\>83% of the changes), whilst the other SNPs were not so consistently selected (\<32% of the changes; [Supplementary Figure S5B and C](#sup1){ref-type="supplementary-material"}). These results suggest the robustness of the original SNP selections against modification of the manners to calculate 'appearance probability'.

Direct estimation of prediction accuracy
----------------------------------------

Next, using these robustly selected informative SNP selections, we directly examined how accurately these SNP sets could predict oxytocin efficacy. We first found that the regressions using the selected SNP sets were well fitted to every type of oxytocin response (*P*~Bonferroni-corrected~ \< 0.05 in *F* tests, adjusted *R*^2^ \> 0.27; [Supplementary Table S2](#sup1){ref-type="supplementary-material"}), and confirmed that the effects predicted in the regressions were significantly correlated with the empirically observed effects (*r* ≥ 0.61, *P*~Bonferroni-corrected~ \< 0.05; [Figure 3A](#nsw150-F3){ref-type="fig"}). Note that the independence between the training and test data was preserved here, because the same SNP sets were selected as the most informative SNP sets across all different training datasets for each oxytocin response ([Figure 2C](#nsw150-F2){ref-type="fig"}).

Moreover, these informative SNP sets enabled us to distinguish individuals who were above-average responsive to oxytocin from those who were below-average responsive to the neuropeptide (\>71% accuracy, *P*~Bonferroni-corrected~ \< 0.05 in binominal tests; [Figures 3B and C](#nsw150-F3){ref-type="fig"}, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Furthermore, such accurate predictions of the oxytocin efficacies were consistently achieved regardless of the order of the administration of oxytocin and placebo (*r* ≥ 0.57; [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

Taken together, these results show that the selected *OXTR* SNP sets can accurately predict behavioral and neural oxytocin responses in high-functioning adults with ASD.

Functional dissociations between different *OXTR* SNPs
------------------------------------------------------

Finally, we investigated biological functions of individual *OXTR* SNPs in terms of oxytocin's effects in autism by examining the weights assigned to the SNPs in the regression analysis (e.g. if a SNP is assigned a positive regression weight, the SNP is supposed to enhance oxytocin efficacy).

As a result, we first found that all the weight values were significantly different from zero \[*t*~(3)~ \> 7.6, *P*~Bonferroni-corrected~ \< 0.05 in one-sample *t*-tests\]. Notably, despite the independence between different types of oxytocin effects, the weight directions were the same across the different oxytocin efficacy ([Figure 3D](#nsw150-F3){ref-type="fig"}, [Table 2](#nsw150-T2){ref-type="table"}), providing biological validation to the current observations. Table 2.Effects of *OXTR* SNPs on oxytocin efficacy**Effects of major alleles on oxytocin efficacy: increase (+) or decrease (--)SNPMajor alleleNonverbal communication scoreResponse smoothnessACC activitydmPFC activitydmPFC--ACC connectivityNAA level in ACC**rs4686300CC**+**rs237877/rs237878CC/TT**--**rs11706648AA**++++**rs237887GG**--**rs2254295/rs2254298/rs2268491TT/GG/CC**----------**rs11131149GG**----**rs53576GG**++++++**rs2268495/rs4686302GG/CC**------**rs237900GG**+**rs17049528/rs6777726GG/GG**++**[^1]

In particular, the weights assigned to rs53576 were consistently positive in all the regressions for every oxytocin response, whereas weights for rs2254298 were always negative. These results suggest that individuals with the major allele type (GG) in rs53576 were generally more responsive to oxytocin than those with the minor alleles (GA/AA), whilst individuals with the minor alleles for this SNP (GA/AA) are more responsive to the neuropeptide in both behavioral and neural manners than those with the major allele (GG).

This distinct difference in the effects on oxytocin responsiveness between these two prominent *OXTR* SNPs was also confirmed by conventional univariate analyses \[*F*~(1,\ 221)~ \> 6.9, *P* \< 0.009 in repeated-measures two-way ANOVA; *t*~(226)~ \> 2.7, *P* \< 0.008 in *posthoc* two-sample *t*-tests; [Figure 4](#nsw150-F4){ref-type="fig"}\]. These results imply dissociable biological functions of different *OXTR* SNPs when oxytocin affects autistic social symptoms (see 'Discussions' section). Fig. 4.Comparison of oxytocin efficacy based on variations of a specific SNP. For the two prominent *OXTR* SNPs ((A) rs2254298 and (B) rs53576), we also performed univariate simple comparisons of the oxytocin efficacy between individuals with major allele and those with minor alleles. The overall trends that were evaluated as a main effect of SNP patters support the results of the original multivariate analyses \[*F*~(1,\ 221)~ \> 6.9, *P* \< 0.009 in two-way ANOVA of normalized oxytocin responses: (major homozygous allele, combined minor alleles) × (six types of oxytocin response)\]. Error bars, SD.

Discussions
===========

In this study, we identified specific *OXTR* SNP combinations that could robustly and accurately predict the magnitude of behavioral and neural effects of oxytocin on social impairments in Japanese high-functioning adult males with ASD. Moreover, these observations were qualitatively reproduced when we used the data recorded from 35 drug-free participants ([Supplementary Materials](#sup1){ref-type="supplementary-material"}, [Supplementary Figures S7 and S8](#sup1){ref-type="supplementary-material"}). Although these findings should be tested in a larger sample size in future studies, the current results provide new biological insights into the functions of several prominent *OXTR* variants, and this analysis procedure would contribute to establishment of future tailor-made precision medicines for ASD.

Biological implication
----------------------

The current observations imply biological functions of several *OXTR* SNPs in ASD. In particular, the results summarized in [Table 2](#nsw150-T2){ref-type="table"} suggest seemingly distinct biological functions of two prominent *OXTR* SNPs, rs2254298 and rs53576, whose associations with ASD and their social behaviors have been repeatedly reported ([@nsw150-B16]; [@nsw150-B26]; [@nsw150-B53]; [@nsw150-B24]). Although such associations may depend on ethnicity ([@nsw150-B42]; [@nsw150-B54]; [@nsw150-B7]), previous studies suggested that AA/AG allele types of rs2254298 and rs53576 (minor alleles for both SNPs) are relevant to atypical brain anatomy and relatively impaired social skills ([@nsw150-B39]; [@nsw150-B21]; [@nsw150-B41], [@nsw150-B42]; [@nsw150-B35]), and are more likely to be observed in individuals with ASD than in controls ([@nsw150-B51]; [@nsw150-B30]; [@nsw150-B53]; [@nsw150-B32]). Such relationships between specific *OXTR* SNP and impairment of social skills in ASD were also seen in the current dataset ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}): if baseline responses to the current social task are close to behavioral and neural responses to placebo, ASD individuals with AA/AG allele in rs2254298 and rs53576 showed more severely impaired social behaviors and less neural activity in the medial prefrontal cortex than those with GG allele \[*F*~(1,221)~ ≥ 7.3, *P* \< 0.008 in repeated-measures two-way ANOVA\].

Considering these previous findings and current observations, this study appear to indicate (i) that individuals with rs2254298A tend to have atypical neural systems for social cognition, show autistic symptoms, and be responsive to intranasal oxytocin administration, (ii) whilst those with rs53576A also tend to have atypical social cognition and be found in the autistic population, but they are likely to be less responsive to oxytocin than those with rs53576GG. This dissociation may also imply that, at least in the current Japanese participants, rs53576A might induce more severe functional impairments in oxytocin receptor than rs2254298A.

Comparison between the six markers
----------------------------------

The adjusted *R*^2^s for neurobiological responses were larger than those for behaviors ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), and Akaike Information Criteria for these regressions ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}) were lower in the neurobiological biomarkers than in behaviors. These comparisons suggest that genetic information more suitably fits to neural responses than to behavioral ones ([@nsw150-B1]), which is reasonable if we assume that genetic variations first induce neurobiological changes that thereby result in behavioral alterations. Given such high sensitive neural responses, drug trials might need to include neurobiological indices as their outcomes ([@nsw150-B52]).

Clinical implication and significances
--------------------------------------

Clinically, the current results could help developments of precision medicines for ASD. In contrast to single-dose oxytocin administration ([@nsw150-B18]; [@nsw150-B14]; [@nsw150-B12]; [@nsw150-B4], [@nsw150-B3]; [@nsw150-B44]), trials that continually administered oxytocin to ASD individuals appear to have experienced difficulty in detecting sufficient behavioral oxytocin effects ([@nsw150-B2]; [@nsw150-B9]; [@nsw150-B17]). This discrepancy may indicate that continual administration of oxytocin amplifies the individual variability in sensitivity to the neuropeptide. Therefore, for practical clinical application of oxytocin, it is increasingly necessary to identify personal characteristics that determine individual oxytocin efficacy. In this regard, our results suggest that, at least in the Japanese population, examining specific *OXTR* SNPs in [Table 2](#nsw150-T2){ref-type="table"} prior to actual oxytocin administration may help us to infer their oxytocin efficacy and to prevent ineffective pharmaceutical intervention.

Limitation
----------

The generalization capability of the current results may be restricted by the participants' ethnicity (i.e. Japanese). Previous studies suggested ethic differences in the ASD--*OXTR* associations ([@nsw150-B7]; [@nsw150-B53]) and in relationships between *OXTR* variants and brain architecture ([@nsw150-B42]; [@nsw150-B54]). Therefore, we need to be cautious when generalizing the current observations to non-Asian groups.

Another limitation is the sample size. Previous pharmacogenetics studies shown some strong genome-wide associations in a relatively small sample size ([@nsw150-B8]), and the current findings were robust against changes in analysis parameters and datasets. However, it is also the case that the current sample size may be insufficient for accurate regression analyses using a larger number of SNPs. Therefore, to examine more SNPs with sufficiently small inter-SNP multicollinearity, future studies will need to use larger sample.

Conclusion
==========

We have examined associations between *OXTR* SNP variations and oxytocin efficacy in autism, and identified specific SNP sets that accurately predicted behavioral/neural responses to oxytocin in ASD. Although larger studies using different ethnic populations are necessary, the current findings and approach provide novel insight into neurobiological functions of ASD-related genetic variants, and would help the development of future precision medicines for ASD.
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[^1]: ACC, anterior cingulate cortex; dmPFC, dorsal medial prefrontal cortex; NAA, N-acetylaspartate.
